Koers Lonza Group AG Swiss Exchange
Aandelen
CH0013841017
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- CHF | - |
Omzet 2024 * | 6,65 mld. 7,35 mld. 6,83 mld. | Omzet 2025 * | 7,5 mld. 8,29 mld. 7,7 mld. | Marktkapitalisatie | 37,47 mld. 41,39 mld. 38,45 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 904 mln. 998 mln. 928 mln. | Nettowinst (verlies) 2025 * | 1,11 mld. 1,23 mld. 1,14 mld. | EV/omzet 2024 * | 5,96 x |
Nettoschuld 2024 * | 2,18 mld. 2,4 mld. 2,23 mld. | Nettoschuld 2025 * | 2,47 mld. 2,73 mld. 2,53 mld. | EV/omzet 2025 * | 5,32 x |
K/w-verhouding 2024 * |
42
x | K/w-verhouding 2025 * |
33,7
x | Werknemers | - |
Dividendrendement 2024 * |
0,87% | Dividendrendement 2025 * |
1% | Vrij verhandelbaar | 95,87% |
Recentste transcriptie over Lonza Group AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25-04-17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01-12-21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16-04-14 |
Director/Board Member | 66 | 16-04-14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,86 mld. | |
-3,46% | 40,66 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. | |
+19,33% | 11,64 mld. |
- Beurs
- Aandelen
- Koers LONN
- Koers